AtaiBeckley (ATAI) Proxy filing summary

Executive summary

• Entered into a definitive agreement to be acquired by Eli Lilly, marking a major milestone and validating the clinical progress of the lead asset BPL-003 and the broader pipeline.

• Transaction aims to accelerate the delivery of novel neuroplastogen therapies for mental health conditions to more patients globally.

• The merger is expected to create immediate and potential future value for shareholders and employees, including contingent value rights (CVRs).

• Both companies will continue to operate independently until the transaction closes, pending shareholder and regulatory approvals.

Voting matters and shareholder proposals

• Stockholders will be asked to approve the merger agreement at a special meeting, with proxy materials to be distributed following SEC filing.

• Shareholders are encouraged to review the proxy statement and related materials for important information regarding the transaction.

Board of directors and corporate governance

• Directors, executive officers, and certain employees may be considered participants in the proxy solicitation for the merger.

• Information on director and executive officer holdings and compensation is available in prior SEC filings and will be updated in the proxy statement.